NeuroD1-GPX4 signaling leads to ferroptosis resistance in hepatocellular carcinoma
PLOS Genetics · 2023
DOI: 10.1371/journal.pgen.1011098 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Genetics, 2023. Verfasst von Ping Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Ferroptosis, Liver Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission.
Abstract (Originalsprache)
Cell death resistance is a hallmark of tumor cells that drives tumorigenesis and drug resistance. Targeting cell death resistance-related genes to sensitize tumor cells and decrease their cell death threshold has attracted attention as a potential antitumor therapeutic strategy. However, the underlying mechanism is not fully understood. Recent studies have reported that NeuroD1, first discovered as a neurodifferentiation factor, is upregulated in various tumor cells and plays a crucial role in tumorigenesis. However, its involvement in tumor cell death resistance remains unknown. Here, we found that NeuroD1 was highly expressed in hepatocellular carcinoma (HCC) cells and was associated with tumor cell death resistance. We revealed that NeuroD1 enhanced HCC cell resistance to ferroptosis, a type of cell death caused by aberrant redox homeostasis that induces lipid peroxide accumulation, leading to increased HCC cell viability. NeuroD1 binds to the promoter of glutathione peroxidase 4 ( GPX4 ), a key reductant that suppresses ferroptosis by reducing lipid peroxide, and activates its transcriptional activity, resulting in decreased lipid peroxide and ferroptosis. Subsequently, we showed that NeuroD1/GPX4-mediated ferroptosis resistance was crucial for HCC cell tumorigenic potential. These findings not only identify NeuroD1 as a regulator of tumor cell ferroptosis resistance but also reveal a novel molecular mechanism underlying the oncogenic function of NeuroD1. Furthermore, our findings suggest the potential of targeting NeuroD1 in antitumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, China.
- The 111 Project Laboratory of Biomechanics and Tissue Repair, College of Bioengineering, Chongqing University, Chongqing, China.
- Department of Hepatobiliary and Pancreatic Oncology, Chongqing University Cancer Hospital, Chongqing University, Chongqing, China.
- Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing University, Chongqing, China.
ORCID-Profile: Ping Huang, Wei Duan, Cao Ruan, Rendy Hosea, Vivi Kasim
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission
Zitieren
APA
Huang, P., Duan, W., Ruan, C., Wang, L., Hosea, R., Wu, Z., Zeng, J., Wu, S., & Kasim, V. (2023). NeuroD1-GPX4 signaling leads to ferroptosis resistance in hepatocellular carcinoma. PLOS Genetics. https://doi.org/10.1371/journal.pgen.1011098
Vancouver
Huang P, Duan W, Ruan C, Wang L, Hosea R, Wu Z, et al. NeuroD1-GPX4 signaling leads to ferroptosis resistance in hepatocellular carcinoma. PLOS Genetics. 2023. doi:10.1371/journal.pgen.1011098
BibTeX
@article{Huang2023,
author = {Huang, Ping and Duan, Wei and Ruan, Cao and Wang, Lingxian and Hosea, Rendy and Wu, Zheng and Zeng, Jianting and Wu, Shourong and Kasim, Vivi},
title = {NeuroD1-GPX4 signaling leads to ferroptosis resistance in hepatocellular carcinoma},
journal = {PLOS Genetics},
year = {2023},
doi = {10.1371/journal.pgen.1011098}
}
EUVIMED